Search clinical trials for: Recombinant hyaluronidase

Total 3477 results

National Cancer Institute (NCI)

Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Takeda
Takeda Development Center Americas, Inc.

Not yet recruiting

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

AL Amyloidosis
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma

United States
ViiV Healthcare

Recruiting

A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

HIV Infections

United States
University of Southern California
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial Serous Adenocarcinoma | Uterine Corpus Carcinosarcoma

United States, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Primary Mediastinal Large B-Cell Lymphoma

United States, Canada, Australia, Puerto Rico
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma | RISS Stage I Plasma Cell Myeloma | RISS Stage II Plasma Cell Myeloma

United States
Abdullah Khan

Terminated

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (PALOMA-3)

Advanced or Metastatic Non-small Cell Lung Cancer

Italy, United States, Germany, Japan, China, Korea, Republic of, Israel, Portugal, Taiwan, Thailand, Malaysia, United Kingdom, Australia, Turkey, Poland, Spain, Brazil, Canada, Argentina, France
Hoffmann-La Roche
BioLineRx, Ltd.; Halozyme Therapeutics

Active, not recruiting

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

United States, United Kingdom, Australia, Korea, Republic of, Taiwan, Israel, Spain
Takeda

Active, not recruiting

A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Multifocal Motor Neuropathy (MMN)

Japan
Janssen Research & Development, LLC

Completed

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Netherlands, Sweden, Denmark, France
Takeda

Active, not recruiting

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Primary Immunodeficiency Diseases (PID)

Japan
Thomas Jefferson University
Janssen Scientific Affairs, LLC

Active, not recruiting

Home Based Daratumumab Administration for Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI); Halozyme Therapeutics

Completed

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) (VRC 609)

HIV Antibodies

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
Alexion Pharmaceuticals, Inc.

Completed

Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers

Healthy

United Kingdom
Takeda
Takeda Development Center Americas, Inc.; Baxalta Innovations GmbH, now part...

Completed

A Study of TAK-881 in Healthy Adults

Healthy Volunteers

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

Neoplasms by Site

United States, Mexico, Italy, Argentina, Brazil, Chile, France, Netherlands, New Zealand, Poland, Spain, United Kingdom
ViiV Healthcare

Completed

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

HIV Infections

United States, New Zealand
GWT-TUD GmbH

Completed

Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO) (FIGARO)

Primary Immunodeficiency | Secondary Immune Deficiency

Germany, Italy, France
Takeda

Completed

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Completed

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Spain, Canada, Poland, Italy, Serbia, Germany, Mexico, Turkey, United Kingdom, Czechia, France, United States, Argentina, Brazil, Colombia, Denmark, Greece, Slovakia
BMI Korea

Completed

Evaluate the Safety and Tolerability of a Single-dose Administration of BMI2004 Inj.

Health, Subjective

Korea, Republic of
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Completed

A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

United States, Israel, Canada, Spain, Czechia, Croatia, Poland, Italy, Serbia, Germany, Argentina, Mexico, Turkey, United Kingdom, Brazil, France, Greece, Slovakia, Colombia, Denmark, Norway, Sweden
Halozyme Therapeutics

Completed

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

Dermatitis, Allergic Contact

United States
Halozyme Therapeutics

Completed

Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

Bladder Cancer

United States
Shire
Halozyme Therapeutics

Completed

A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase

Hereditary Angioedema

United States
Shire

Completed

Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks

Hereditary Angioedema (HAE)

United States, Germany, Spain, Sweden
Baxalta now part of Shire

Completed

Gammagard Liquid and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States, Canada
Baxalta now part of Shire

Completed

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Exposure During Pregnancy

Poland, Czechia, United States, Germany, Slovakia
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR); Stem Cell Network

Active, not recruiting

The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial (ENACT-AMI)

Anterior Wall Myocardial Infarction

Canada
Halozyme Therapeutics

Terminated

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Carcinoma

Korea, Republic of, United States, Taiwan, United Kingdom, Israel, France, Germany, Netherlands, Canada, Spain, Australia, Brazil, Belgium, Croatia, Czechia, Denmark, Estonia, Hungary, Italy, Latvia, Lithuania, Poland
Eisai Inc.
Halozyme Therapeutics

Terminated

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Halozyme Therapeutics

Terminated

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic | Gallbladder Adenocarcinoma

United States, Korea, Republic of, Thailand
Halozyme Therapeutics

Completed

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

Gastric Cancer | NSCLC

United States
PH Research, S.L.

Terminated

A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma

Spain
Scripps Health

Terminated

PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer (HALO-IST)

Pancreatic Adenocarcinoma Non-resectable

United States
Halozyme Therapeutics

Completed

Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
Halozyme Therapeutics

Completed

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

Type 1 Diabetes Mellitus

United States

Search clinical trials for: Recombinant hyaluronidase

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations